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Objectives. This study investigated the efficacy and tolerability 
of low energy shocks for termination of atrial fibrillation in 
patients, using an endocardial electrode configuration that em- 
braced both atria. 
Background. In animals, low energy biphasic shocks delivered 
between electrodes in the coronary sinus and right atrium have 
effectively terminated atrial fibrillation. If human defibrillation 
thresholds are sufficiently low, atrial defibrillation could be 
achieved in conscious patients using an implanted device. 
Methods. Twenty-two consecutive patients with stable atrial 
fibrillation were studied during electrophysiologic testing. Bipha- 
sic R wave synchronous shocks were delivered between large 
surface area electrodes in the coronary sinus and high right 
atrium, using a step-up voltage protocol starting at 10 or 20 V and 
increasing to a maximum of 400 V. Patients were conscious at the 
start of the study and were asked to report on symptoms but were 
sedated later if shocks were not tolerated. 
Results. Cardioversion was achieved in all 19 patients who 
completed the study, with a mean (-+SD) leading-edge voltage of 
237 -+ 55 V (range 140 to 340) and mean energy of 2.16 _+ 1.02 J 
(range 0.7 to 4.4). The mean maximal shock delivered without 
sedation was 116 ± 51 V (range 60 to 180). No proarrhythmia or 
mechanical complications occurred. 
Conclusions. The delivery of biphasic R wave synchronous 
shocks between the high right atrium and coronary sinus can 
terminate atrial fibrillation with very low energies. General an- 
aesthesia is not required, and a minority of fully conscious 
patients are able to tolerate this method of cardioversion. 
(J Am Coll Cardiol 1995;25:1347-53) 
Of the cardiac arrhythmias, atrial fibrillation is by far the most 
common and is responsible for the most hospital admissions 
and days in hospital (1). Although tolerated by many patients, 
atrial fibrillation can cause disabling symptoms and is perhaps 
the most important treatable cause of stroke (2,3). Both 
functional capacity and left ventricular function improve after 
the restoration and maintenance of sinus rhythm, even in 
patients with a previously controlled ventricular ate (4-6). 
Antiarrhythmic drugs are of limited efficacy (7-10), frequently 
cause adverse reactions and side effects and carry the risk of 
both atrial and ventricular proarrhythmia (8,11-13). Nonphar- 
macologic approaches to atrial fibrillation are, therefore, gain- 
ing attention. His bundle ablation and the corridor operation 
(14) do not restore atrial function or affect the thromboem- 
bolic risk, and the maze procedure (15) is a major surgical 
undertaking associated with significant morbidity. 
An implantable atrial defibrillator could have significant 
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advantages over these approaches for patients with sustained 
symptomatic episodes of paroxysmal trial fibrillation, but the 
shocks delivered would need to be of sufficiently low energy to 
be tolerated in full consciousness. A technique to achieve this 
may also have applications in the acute care of repeated atrial 
fibrillation episodes. Several strategies have been investigated 
(16-21) in experimental trial fibrillation to deliver shocks 
closer to the atria and reduce the defibrillation threshold. The 
most efficient use biphasic shocks and include both atria in the 
electric field while limiting energy delivery to other tissues. The 
shock strength required for endocardial atrial defibrillation 
using this method in patients and the tolerability of such shocks 
are unknown. 
We, therefore, investigated the clinical efficacy of biphasic 
low energy shocks delivered between transvenous catheters in 
the right atrium and coronary sinus for the cardioversion of 
sustained but not chronic atrial fibrillation and the degree of 
discomfort caused by such shocks. 
Methods  
Patients. The protocol was carried out in patients under- 
going invasive lectrophysiologic studies. Patients were consid- 
ered eligible if sustained atrial fibrillation of <3 days in 
duration was present at the commencement of the electro- 
physiologic study or if atrial fibrillation was induced during 
the course of the study and lasted for at least 15 min. All 
©1995 by the American College of Cardiology 0735-1097/95/$9.50 
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Figure I. Posteroanterior chest radiograph demonstrating defibrilla- 
tion electrode configuration. CS = electrode in coronary sinus; RA = 
right atrial electrode; RV = right ventricular pace/sense electrode. 
antiarrhythmic drugs (including digitalis) were discontinued 
for at least 5 half-lives before the electrophysiologic study. 
Patients were excluded if they had a history of stroke or 
thromboembolism. Our usual procedure was followed with 
regard to anticoagulation. Patients who develop atrial fibrilla- 
tion during the electrophysiologic study do not undergo anti- 
coagulation, but those who develop sustained atrial fibrillation 
beforehand (usually on discontinuation f antiarrhythmic ther- 
apy) undergo temporary anticoagulation. Anticoagulation is
then discontinued before insertion of transvenous sheaths. The 
study protocol was approved by the District Medical Ethics 
Committee, and all patients gave written informed consent 
before the commencement of the study. 
Protocol. Two identical custom-made 6F catheters (Electro- 
Catheter Inc.) were used to deliver defibrillation shocks. Each 
had nine 5-ram platinum segments eparated by 2-mm flexible 
plastic spacers. These were connected so as to constitute a single 
electrode length of 6 cm and total surface area 2.83 cm 2. The 
catheters were positioned under fluoroscopic guidance, and their 
positions were confirmed radiographically (Fig. 1). The left atrial 
catheter was introduced through asheath in the left subclavian or 
right internal jugular vein, advanced as far as it would easily pass 
into the coronary sinus and then withdrawn -1  cm so that its tip 
would not exert pressure on the vessel wall. The right atrial 
catheter was introduced through a sheath in the right femoral 
vein and advanced into the high right atrium, with the tip in the 
appendage and, where possible, with the electrode section against 
the anterolatcral trial wall. In the first 15 patients, a pacing 
catheter, advanced from the right femoral vein and positioned in 
the right ventricular apex, was used to provide R wave synchro- 
nization and deliver backup ventricular demand pacing at a rate 
of 40 beats/min. In later patients, aventricular lead was not used, 
and the surface electrocardiogram (ECG) was used for R wave 
synchronization. 
The defibrillation catheters were connected (right atrium 
negative, left atrium positive) to a custom-made external atrial 
defibrillator (XAD, InControl Inc.). This delivers a truncated 
exponential shock with the two phases each of 3-ms duration, 
separated by 240/xs, and with a leading-edge voltage program- 
mable between 10 and 400 V. Shocks are synchronized to a 
trigger signal, with a delay of 20 ms. For safety reasons, the 
device was programmed to deliver shocks only after RR 
intervals between 500 and 1,000 ms (see Discussion). The 
external atrial defibrillator calibrates itself on power-up against 
an internal reference capacitor and, after each shock, gives a 
readout of the actual leading-edge voltage, delivered energy 
and impedance. 
After a test shock of 10 or 20 V to verify correct R wave 
synchronization, a sequence of shocks was given, increasing 
from 20 V in 40-V steps, until atrial fibrillation was terminated 
or a 400-V shock was delivered. Shocks were separated by at 
least 1 rain. The surface ECG was recorded continuously onto 
paper at a chart speed of 25 mm/s. Shocks were classified as 
follows (Fig. 2): failure = continuation of atrial fibrillation; 
26o v 
1 a.  
22O V 
b. 
140V 
1 C. 
1000 ms 
Figure 2. Electrocardiographic tracings of delivered shocks: 
immediate (a) and delayed (h) cessation of atrial fibrillation 
after shock delivery and (c) unsuccessful shock. 
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immediate success = no evidence of atrial fibrillation after 
shock delivery; delayed success = continued atrial fibrillation 
after shock delivery, terminating within seconds. In this case, 
the time from the shock to the first P wave was noted. 
In some patients, intravenous premedication (2.5 mg of 
diamorphine or 2.5 mg of midazolam) was given before 
insertion of transvenous sheaths for the electrophysiologic 
study. This was always at least 2 h before the commencement 
of the shock protocol. To evaluate the tolerability of the 
defibrillation shocks, no further sedation was given before the 
first shock, so that all patients were fully conscious at the outset 
of the study and able to report any symptoms experienced, 
according to the following scale: 1 = shock not felt; 2 = shock 
felt, no discomfort; 3 = mild discomfort; 4 = moderate 
discomfort; 5 = severe discomfort. After each shock, patients 
were given the option of requesting sedation (intravenous 
midazolam) before the study continued. The last shock to be 
delivered before any such request, and all shocks given after 
sedation (however light), were scored as 5. 
Continuous variables were compared using the Student 
test, and the Fisher exact est was used for discrete variables; 
p < 0.05 was considered statistically significant. 
Resu l ts  
Patients. Twenty-two patients entered the study and were 
classified into two groups. Group 1 included 18 patients in 
whom atrial fibrillation was induced by catheter manipulation 
or electrical stimulation during electrophysiologic study (mean 
[±SD] duration of atrial fibrillation 35 _ 19 min, range 15 to 
75). Thirteen of these patients also had a history of docu- 
mented spontaneous atrial fibrillation. Group 2 included four 
patients with spontaneous atrial fibrillation at the beginning of 
the eleetrophysiologic study (duration of atrial fibrillation 35 - 
25 h, range 18 to 72). The clinical characteristics of the two 
groups are shown in Table 1. 
Outcomes. A total of 144 shocks were given (6.5 _+ 1.7 
shocks/patient). The protocol was not completed in three 
patients. In one patient, the procedure was abandoned after 
shocks of up to 340 V failed to restore sinus rhythm. This was 
one of the earliest patients to be studied, and the protocol was 
subsequently amended to allow shocks of up to 400 V to be 
delivered. In the second patient, atrial fibrillation converted to 
atrial flutter > 1 rain after the delivery of the 100-V shock; the 
flutter was terminated by overdrive atrial pacing. In view of the 
long interval between shock delivery and cessation of atrial 
fibrillation, this was considered to be a spontaneous change in 
rhythm rather than a success. The third patient regained sinus 
rhythm -1  rain after the delivery of the 300-V shock and 
immediately before the 340-V shock. Again, this was consid- 
ered to have been a spontaneous cessation of arrhythmia. 
The remaining 19 patients completed the protocol, and 
atrial fibrillation was terminated inevery patient. Sinus rhythm 
resulted in 18 patients, with 13 immediate successes. In five 
patients, there was continued ECG evidence of atrial fibrilla- 
tion immediately after shock delivery, and the time to the first 
Table 1. Clinical Characteristics of 22 Study Patients 
Group 1: Group 2: 
Induced AF Spontaneous AF 
(n=18)  (n=4)  p Value 
Men/women 14/4 3/1 
Age (yr) 
Mean _~ SD 52 _+ 11 64 + 7 0.037 
Range 33-77 56-71 
LA diameter (mm) 
Mean _+ SD 3.7 -+ 0.7 4.7 -+ 0.7 0.013 
Range 2.5-4.8 4.2-5.6 
AF duration (h) 
Mean _+ SD 0.58 _+ 0.32 35 _+ 25 0.0003 
Range 0.25-1.25 18-72 
Documented clinical AF 13 (72%) 4 (100%) 0.54 
Structural heart disease 1.00 
IHD 1 1 
ASD 1 0 
DCM 1 0 
Other arrhythmias 0.11 
AT 1 0 
SND 1 0 
AFL 1 0 
AVNRT 2 0 
AVRT 3 0 
VT 1 0 
"Lone" AF 9 (50%) 3 (75%) 0.59 
Data presented are mean value -- SD or number (%) of patients. AF = atrial 
fibrillation; AFL = atrial flutter; ASD = repaired atrial septal defect; AT = 
(automatic) atrial tachycardia; AVNRT = atrioventricular node reentrant tachy- 
cardia; AVRT = atrioventrieular reentrant tachycardia; DCM = dilated eardiomy- 
opathy; IHD = ischemic heart disease; LA = left atrial; "Lone" AF = no 
structural cardiac disease or arrbythmia other than atrial fibrillation; SND = 
sinus node disease; VT = ventricular tachycardia. 
P wave was 2,500 +_ 1,400 ms (range 1,600 to 4,900). Because 
atrial fibrillation had been present for between 15 and 60 min, 
this was unlikely to be a chance occurrence, and these cases 
were considered to be delayed successes. In the remaining 
patients, atrioventricular (AV) node reentrant achycardia 
resumed immediately after the shock--this arrhythmia was 
virtually incessant in this patient and was the indication for the 
electrophysiologic study. 
Electrical variables for defibrillation. The defibrillation 
impedance was calculated for each patient as the mean of the 
impedances measured at each shock--there was very little 
variation between shocks (mean of standard eviations for 
each patient = 2.9 ohms). The impedance did not differ 
significantly between patients with induced and spontaneous 
atrial fibrillation (56.9 _+ 7.5 and 56.3 _+ 7.6 ohms, respectively, 
p = 0.89), nor between patients with immediate and delayed 
success in cardioversion (57.7 +_ 8.0 and 58.3 _+ 2.7 ohms, 
respectively, p = 0.87). The mean leading-edge voltage of 
successful shocks was 237 _+ 55 V (range 140 to 340), and their 
mean delivered energy was 2.16 _+ 1.02 J (range 0.7 to 4.4). 
There was no significant difference between induced and 
spontaneous atrial fibrillation in the leading-edge voltages 
(230 ± 55 and 260 ± 57 V, respectively, p = 0.36, 95% 
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confidence limits [CL] for difference -95, +37) or energies 
(2.05 _+ 0.97 and 2.55 _+ 1.28 J, respectively, p = 0.40, CL 
-1.72,  + 0.73) at which defibrillation was achieved (Fig. 3). 
These measures were lower in shocks achieving delayed suc- 
cess than in those achieving immediate success, but the differ- 
ences were of borderline significance (196 + 54 vs. 251 _+ 50 V, 
p = 0.05, CL -1,  +111; 1.50 _+ 0.78 vs. 2.39 +_ 1.02 J, p = 0.09, 
CL -0.17, 1.96, respectively) (Fig. 4). 
Safety and tolerability. No adverse vents, including ven- 
tricular arrhythmias, occurred during any of the procedures. 
Immediately after the larger shocks, there was some evidence 
of sinus and AV node slowing. After successful shocks, the 
longest sinus pause was 2.52 s, and the slowest heart rate was 
43.1 beats/rain (measured over the first 5 beats). After unsuc- 
cessful shocks, the longest RR interval was 1.32 s, and the 
lowest heart rate was 50.3 beats/rain. Paced beats were deliv- 
ered in 2 of the 15 patients with temporary ventricular pacing. 
In both patients, this was due to a sinus pause immediately 
after successful shocks. A single paced beat was seen in one 
patient and two paced beats in the other. No shock caused 
sustained bradycardia. 
The symptoms caused by shocks are shown in Figure 5. All 
but three patients were able to sense the smallest shock 
delivered (10 or 20 V), and the degree of discomfort always 
increased with shock strength. The largest shock delivered in 
full consciousness was 116 _+ 51 V and varied considerably 
between 60 V (0.1 J) in seven patients and 180 V (1.1 to 1.2 J) 
in six. In 17 patients, this was less than the voltage required for 
cardioversion, so that some degree of sedation was required. In 
two patients, no sedation was given. In one of these patients, 
the successful shock was the first to cause severe discomfort, 
and in the other, it caused only moderate discomfort. In the 
remaining three patients, the defibrillation threshold was not 
established because of discontinuation of the protocol. No 
patient reported any residual discomfort after the procedure, 
and there was no echocardiographic evidence of cardiac 
trauma after the procedure. 
Figure 3. Leading-edge voltages and delivered energies in patients 
with induced and spontaneous ( pont.) atrial fibrillation. Vertical bars 
and circles = mean value _+ SD. 
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Figure 4. Leading-edge voltages and delivered energies in patients in 
whom immediate (immed.) and delayed success was observed for atrial 
defibrillation. Vertical bars and circles = mean value _+ SD. 
Discuss ion  
Background. Electrical cardioversion by transthoracic ca- 
pacitor discharge has been a standard treatment for atrial 
fibrillation since its description by Lown et al. (22). However, 
general anesthesia s an almost universal prerequisite because 
energies of >100 J are generally needed, even with adjunctive 
drug therapy (23). Less energy is required if the electric field is 
closer to, or within, the atria. In dogs, defibrillation thresholds 
of <1.5 J were obtained by placing a catheter in the esophagus 
(16), but transesophageal c rdioversion i humans requires up 
to 100 to 200 J to achieve 80% success (24). Cardioversion has 
also been achieved in a canine model using endocavitary 
shocks with energies of <5 J (17,18). In sheep (whose heart 
size is similar to that of humans), 80% success was achieved 
with 2.5-J shocks delivered between the right atrium and a skin 
patch (19). A systematic omparison of several electrode 
configurations and shock waveforms was performed in a sheep 
model of paroxysmal trial fibrillation by Cooper et al. (20). 
The lowest thresholds were obtained using configurations 
embracing both atria. Biphasic shocks were delivered between 
the right atrial appendage and the coronary sinus, and cardio- 
version was achieved with thresholds of 1.3 ± 0.4 J. In patients, 
right atrial unipolar shocks can be used to cardiovert chronic 
atrial fibrillation that is resistant o transthoracic shocks, but 
energies of 200 to 300 J are needed (25), and early attempts at 
low energy cardioversion i humans were uniformly unsuccess- 
ful (26). However, Keane et al. (21) recently reported atrial 
defibrillation thresholds of <1 J using biphasic shocks deliv- 
ered between paddle electrodes on the left and right atrial 
epicardial surfaces in patients with atrial fibrillation induced 
artificially during cardiopulmonary b pass. 
Efficacy. In the present study, biphasic shocks were deliv- 
ered between defibrillation electrodes in the coronary sinus 
and high right atrium of patients with paroxysmal atrial 
fibrillation lasting between 15 rain and 3 days. The electrodes 
used were of simple design and low surface area compared 
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Figure 5. Tolerability ofshocks. For each patient, he 
lowest leading-edge voltage responsible for each level 
of discomfort is shown, along with the voltage at which 
cardioversion was obtained. Atrial fibrillation i  Pa- 
tient 3 was not cardioverted byshocks up to 340 V, 
and Patients 4 and 6 did not complete the study 
because of spontaneous return of sinus rhythm (see 
text for details). 
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with coil electrodes currently used in implantable cardioverter- 
defibrillator systems. Nevertheless, termination of atrial fibril- 
lation was achieved using energies generally between 1 and 
3 J--two orders of magnitude lower than those required with 
a transthoracic approach. Cardioversion failed in only one 
patient with shocks of up to 340 V. The protocol was subse- 
quently amended to allow a maximal output of 400 V, and 
although this voltage has not been required since, it is not 
known whether it may have been effective in this patient. 
Most of the patients in whom the arrhythmia was artificially 
induced on the occasion of this study had a history of docu- 
mented, spontaneously occurring atrial fibrillation. Further- 
more, the patients investigated uring spontaneous atrial 
fibrillation did not require significantly higher voltage shocks 
than those with induced atrial fibrillation, despite their greater 
age and left atrial diameter and longer duration of their 
arrhythmia. Although the numbers tudied were small, this 
would indicate that induced atrial fibrillation in susceptible 
patients provides an acceptable model of the spontaneous 
arrhythmia for the purpose of further esearch into internal 
cardioversion. 
In five patients, adelay (up to 4.9 s) was observed between 
shock delivery and cessation of atrial fibrillation. A long period 
of stable atrial fibrillation was required before the delivery of 
the first shock, and coincidental spontaneous reversion to sinus 
rhythm can almost certainly be excluded as an explanation of 
the observation. A similar delay in response is frequently 
observed when ventricular fibrillation is terminated by implant- 
able devices. With external direct current shocks, the occur- 
rence may not be recognized because the ECG signal tends to 
be saturated immediately after shock delivery. The likeliest 
explanation for the phenomenon is that the electric urrent is 
not quite sufficient to defibrillate a critical mass of atrial tissue, 
so that the fibrillating wavelets are reduced in number but not 
abolished. Depending on the local conduction properties and 
refractory state of the atrial myocardium that they encounter, 
the surviving wavelets may either einitiate stable atrial fibril- 
lation or be extinguished. This explanation is supported by the 
observation that in the present study, shocks leading to delayed 
cardioversion tended to be of lower voltage than those achiev- 
ing immediate success. An alternative xplanation is that in 
these cases cardioversion is not a purely electrical phenome- 
non but is instead mediated by local neuroendocrine mecha- 
nisms. 
Safety. Mechanical complications ofhigh energy endocavi- 
tary shock delivery (especially in the region of the coronary 
sinus) are generally related to barotrauma. This occurs when 
the current density is sufficient o give rise to arcing and the 
formation of a gas bubble, and can cause coronary sinus 
rupture and cardiac tamponade (27). Barotrauma does not 
occur with transvenous implantable cardioverter-defibrillator 
systems, which use lower energies and large surface area 
electrodes; and the use of coronary sinus defibrillation leads in 
such systems has been found to be safe (28). In the present 
study, high surface area electrodes and shocks of even lower 
energy were used. No mechanical complications occurred, and 
although the number of patients was limited, the risk of cardiac 
trauma using this technique appears to be minimal. The other 
significant potential risk with low energy atrial defibrillation is
that of inducing malignant ventricular arrhythmias. The elec- 
tric field generated between the right atrial and coronary sinus 
electrodes i  largely confined to the atria, and this is probably 
the reason for the success of this configuration. However, the 
base of the ventricles i inevitably included in the field to an 
extent, and shocks could, therefore, be proarrhythmic if deliv- 
ered during the ventricular relative refractory period. Such a 
risk is highest with unsynchronized shocks but theoretically 
possible at rapid ventricular rates even with QRS synchroni- 
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zation because of inhomogeneity of ventricular repolarization. 
The risk of ventricular proarrhythmia from synchronized low 
energy biatrial shocks was recently investigated in sheep by 
Ayers et al. (29). Over a range of paced and spontaneous cycle 
lengths and energies, the overall incidence of ventricular 
fibrillation was 0.6% and was confined entirely to shocks 
delivered after RR intervals of <300 ms. In the present study, 
all shocks were synchronized to the surface or endocardial 
QRS complex and were delivered after a ventricular cycle 
length of at least 500 ms. Such an interval always occurred 
within seconds of the decision to shock. In contrast to ventric- 
ular defibrillation, a delay in the cardioversion of atrial fibril- 
lation would not be harmful. However, there may be a long 
delay before a suitable RR interval occurs in patients with a 
sustained rapid ventricular ate, and a requirement for a 
minimal RR interval before a shock may limit the extension of 
the technique to patients with atrial flutter. 
Tolerability. The determinants of discomfort caused by 
intracardiac electric discharges are poorly understood. Early 
experiments with low energy intracardiac shocks failed to find 
a correlation between energy delivered and discomfort (26). 
Conversely, in the present study, the degree of discomfort 
increased steadily with shock strength in all patients. However, 
the intrapatient reproducibility of symptoms was not formally 
assessed. Although the maximal voltage delivered without 
sedation varied greatly between patients, it lay in most cases 
between 100 and 180 V, equivalent to -0.5 to 1.0 J. As shown 
in Figure 5, the shock strengths required for cardioversion 
were not usually sufficiently low to be tolerated without 
sedation but were of the same order of magnitude. The 
leading-edge voltage of shocks is unlikely to be the only 
determinant of symptoms. Pain from shocks may result from 
stimulation of nerve fibers or direct excitation of skeletal 
muscle, and it is possible that lower defibrillation thresholds or 
greater tolerability, or both, may be achieved by fine modifi- 
cations to shock waveforms and the design and locations of 
defibrillation electrodes (e.g., to avoid stimulating the phrenic 
nerve and fibers passing near the coronary sinus ostium). 
Posture, psychologic conditioning and circumstance may also 
affect symptoms and explain why some patients with implanted 
cardioverter-defibrillators are able to tolerate shocks of several 
joules in full consciousness. In the present study, sedation was 
requested by patients in the anticipation of an unknown 
number of further shocks of steadily increasing strength in an 
unfamiliar environment. A verbal warning was given before 
each shock. With an implanted atrial defibrillator, it is unclear 
whether the perception of shocks might be improved by 
familiarity and the expectation of a therapeutic benefit (termi- 
nation of a prolonged symptomatic episode of atrial fibrilla- 
tion) and whether a warning feature or patient control of the 
device would be desirable. 
Applications. Low energy transvenous cardioversion has 
several potential applications. Atrial fibrillation frequently 
occurs during electrophysiologic study and catheter ablation 
procedures. This can be terminated repeatedly without antiar- 
rhythmic drugs (which can influence the study) or the need for 
general anesthesia. Similarly, indwelling temporary defibril- 
lation electrodes could be used to terminate recurrent 
attacks of atrial fibrillation occurring in coronary care unit~ 
or after cardiac surgery. Atrial fibrillation occurs frequent b 
in patients with implanted cardioverter-defibrillators and is 
a common cause of hemodynamic deterioration and inap- 
propriate device therapy (30). The ability to recognize and 
terminate atrial fibrillation with low energy shocks would, 
therefore, be a valuable asset, requiring only the addition of 
a coronary sinus electrode, which is already featured in 
some systems. Finally, patients with recurrent, sustained and 
symptomatic atrial fibrillation unresponsive toconventional 
therapy are frequently treated by AV node ablation. An 
implantable atrial defibrillator may be a superior treatment 
for these patients, preserving the benefits of sinus rhythm 
and avoiding the commitment to lifelong pacemaker ther- 
apy. Such devices have recently been tested in sheep (31) 
and, because of the low stored energy requirement, can be 
made sufficiently small for routine prepectoral implantation 
in humans. The cost of this strategy may not exceed that ot 
AV node ablation and pacemaker implantation. 
Study limitations. The present study was intended to eval- 
uate the feasibility of transvenous low energy atrial defibrilla- 
tion. Although complications, including ventricular proar- 
rhythmia, were not observed, no firm conclusions can be drawn 
regarding the issue of safety because of the small numbers 
involved. Clearly, large-scale cooperative fforts are required 
to examine this critical issue. The "step-up" shock protocol was 
used so that patients could be conscious at the start of the 
study and thus be able to report symptoms. Repeated reinduc- 
tion of atrial fibrillation, with shocks in a randomized order, 
would be necessary to determine the precise relation between 
delivered energy and the probability of success. It is likely that 
this follows a sigmoidal dose-response curve, as in animal 
models of atrial and ventricular fibrillation (32,33). If this curve 
has a steep slope, a genuine defibrillation threshold can be said 
to exist, and a single shock just above this level would have a 
very high probability of success. However, if the slope is 
shallow, it would be possible to achieve cardioversion using a 
series of small shocks, each with a low individual likelihood of 
success but with a cumulatively increasing probability of car- 
dioversion. The delayed cardioversions sometimes observed at 
relatively low energies support this likelihood. Finally, the 
study size was inadequate o determine the effects of clinical 
variables, uch as etiology, atrial diameter and drug therapy, on 
the defibrillation threshold. 
Conclusions. Biphasic shocks delivered between the cor- 
onary sinus and high right atrium are able to terminate 
paroxysmal trial fibrillation. The energies required are very 
low, and no complications have been observed. Although 
cardioversion cannot usually be achieved without any seda- 
tion, general anesthesia s not required. This technique has 
several potential applications, including use in implantable 
devices. 
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